Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Clinical Trial ID NCT00089609

PubWeight™ 3.79‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00089609

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992 4.00
2 Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994 2.17
3 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
4 Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995 1.07
5 Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 2008 0.89
6 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
Next 100